



## Renalytix to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 9, 2024

LONDON and SALT LAKE CITY, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (the "Company") today announced that the Company will be participating in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which will take place February 13-14, 2024 in Snowbird, Utah. Given the format of this event, no formal company presentation is expected. Management will be participating in one-on-one meetings with investors during the event and meetings can be requested through BTIG.

### About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

### For further information, please contact:

#### Renalytix plc

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

#### Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

#### Investec Bank plc (Joint Broker)

Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

#### Walbrook PR Limited

Paul McManus / Alice Woodings

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07407 804 654

#### CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)